Catalyst Pharmaceuticals (CPRX) Corporate presentation summary

Strategic positioning and recognition

• Recognized among America's most successful midsize companies and best places to work in 2025.

• Listed on NASDAQ and included in Deloitte Technology Fast 500 North America 2025.

Patient-centric rare disease focus

• Commercial-stage biopharma focused on rare diseases, prioritizing patient needs in all decisions.

• Offers novel medicines and personalized support programs to improve patient outcomes.

Product portfolio and market leadership

• FIRDAPSE is the only evidence-based approved treatment for LEMS, with >90% prescription compliance.

• AGAMREE, a differentiated corticosteroid for DMD, achieved 227% annual revenue growth and high patient retention.

• FYCOMPA, a first-in-class epilepsy treatment, maintains durable revenue despite generic competition.